Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline

Practical Radiation Oncology

Volumn 5, Issue 3, 2015, Pages 141-148

  Rodrigues, George ^a   Choy, Hak ^b   Bradley, Jeffrey ^c   Rosenzweig, Kenneth E ^d   Bogart, Jeffrey ^e   Curran, Walter J ^f   Gore, Elizabeth ^g   Langer, Corey ^h   Louie, Alexander V ^a   Lutz, Stephen ⁱ   Machtay, Mitchell ^j   Puri, Varun ^c   Werner Wasik, Maria ^k   Videtic, Gregory M M ^l  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f EMORY UNIVERSITY   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ Blanchard Valley Health System   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^k THOMAS JEFFERSON UNIVERSITY   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; MITOMYCIN; PACLITAXEL; VINDESINE;

ACUTE ESOPHAGITIS; ADVANCED CANCER; AMERICAN SOCIETY FOR RADIATION ONCOLOGY; ARTICLE; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; COMORBIDITY; DISTANT METASTASIS; DOSE RESPONSE; DYSPHAGIA; ESOPHAGITIS; EVIDENCE BASED PRACTICE; EXTERNAL BEAM RADIOTHERAPY; HOSPITALIZATION; HUMAN; LIKERT SCALE; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; CONSENSUS; HEALTH CARE ORGANIZATION; LUNG NEOPLASMS; MULTIMODALITY CANCER THERAPY; ONCOLOGY; STANDARDS; UNITED STATES;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; CONSENSUS; DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; RADIATION ONCOLOGY; SOCIETIES, SCIENTIFIC; UNITED STATES;

EID: 84947343697     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2015.02.012     Document Type: Article

References (31)

1. McCloskey P., Balduyck B., Van Schil P.E., Faivre-Finn C., O'Brien M. Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer 2013, 49:1555-1564.
2. Ramnath N., Dilling T.J., Harris L.J., et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143(5 Suppl.):40.
3. Loblaw D.A., Prestrud A.A., Somerfield M.R., et al. American Society of Clinical Oncology Clinical Practice Guidelines: Formal systematic review-based consensus methodology. J Clin Oncol 2012, 30:3136-3140.
4. Qaseem A., Snow V., Owens D.K., Shekelle P. The development of clinical practice guidelines and guidance statements of the American College of Physicians: Summary of methods. Ann Intern Med 2010, 153:194-199.
5. Roswit B., Patno M.E., Rapp R., et al. The survival of patients with inoperable lung cancer: A large-scale randomized study of radiation therapy versus placebo. Radiology 1968, 90:688-697.
6. Sigel K., Lurslurchachai L., Bonomi M., et al. Effectiveness of radiation therapy alone for elderly patients with unresected stage III non-small cell lung cancer. Lung Cancer 2013, 82:266-270.
7. Perez C.A., Pajak T.F., Rubin P., et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987, 59:1874-1881.
8. Petrovich Z., Stanley K., Cox J.D., Paig C. Radiotherapy in the management of locally advanced lung cancer of all cell types: Final report of randomized trial. Cancer 1981, 48:1335-1340.
9. Sause W., Kolesar P., Taylor S., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000, 117:358-364.
10. Dillman R.O., Herndon J., Seagren S.L., Eaton W.L., Green M.R. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996, 88:1210-1215.
11. Curran W.J., Paulus R., Langer C.J., et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103:1452-1460.
12. Non-small Cell Lung Cancer Collaborative Group Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2000, 2:CD002139.
13. Okawara G., Mackay J.A., Evans W.K., Ung Y.C. Management of unresected stage III non-small cell lung cancer: A systematic review. J Thorac Oncol 2006, 1:377-393.
14. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
15. Perez C.A., Stanley K., Grundy G., et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: Report by the Radiation Therapy Oncology Group. Cancer 1982, 50:1091-1099.
16. Perez C.A., Bauer M., Edelstein S., Gillespie B.W., Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986, 12:539-547.
17. Amini A., Lin S.H., Wei C., Allen P., Cox J.D., Komaki R. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiat Oncol 2012, 7:33.
18. Saunders M., Dische S., Barrett A., Harvey A., Griffiths G., Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999, 52:137-148.
19. Saunders M.I., Rojas A., Lyn B.E., et al. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer. Br J Cancer 1998, 78:1323-1328.
20. Baumann M., Herrmann T., Koch R., et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011, 100:76-85.
21. Bradley J., Paulus R., Komaki R., et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617. J Clin Oncol 2013, 31. [abstract 7501].
22. Komaki R., Seiferheld W., Ettinger D., Lee J.S., Movsas B., Sause W. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: Long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys 2002, 53:548-557.
23. Belani C.P., Wang W., Johnson D.H., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2005, 23:3760-3767.
24. Belderbos J., Uitterhoeve L., van Zandwijk N., et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007, 43:114-121.
25. Maguire J., O'Rourke N., McNememin R., et al. SOCCAR: Internationally resonant results from a randomizsed trial based on UK clinical practise. Thorax 2012, 67(Suppl. 2):A47. [abstract S95].
26. Vokes E.E., Herndon J.E., Kelley M.J., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007, 25:1698-1704.
27. Belani C.P., Choy H., Bonomi P., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005, 23:5883-5891.
28. Colin P., Jovenin N., Ganem G., et al. Effect of paclitaxel-carboplatin (PC) consolidation chemotherapy after weekly PC concurrent chemo-radiotherapy (CCR) for patients with locally advanced non-small cell lung cancer (LA NSCLC): 3-year definitive results of the B001-phase III GERCOR-study. J Clin Oncol 2006, 24. [abstract 7112].
29. Hanna N., Neubauer M., Yiannoutsos C., et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008, 26:5755-5760.
30. Yamamoto N., Nakagawa K., Nishimura Y., et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 2010, 28:3739-3745.
31. Wang L., Wu S., Ou G., et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2012, 77:89-96.